VVZ· CzechiatenderOpen · 11 Nov 2026
Selective immunosuppressants - Ravulizumab III.
Institut klinické a experimentální medicíny
Tenders due 11 Nov 2026Tenders due11 Nov 2026
Estimated valueCZK 352,260,000
CPV category33652300
Published07 Oct 2026
ReferenceVVZ:F2026-053438
Notice summary
The subject of the public contract is the supply of medicinal products for parenteral administration containing the active substance ravulizumab (ATC L04AJ02) for the treatment of patients in approved indications according to the SPC valid on the date of submission of bids.
Is this worth bidding on?
Tender Radar scores every tender against your company profile, surfaces the matching services, and flags the ones worth your time — across Europe and beyond. Sign in to see the relevance match and full AI analysis for this opportunity.